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http://dx.doi.org/10.1016/j.ccr.2012.08.013SUMMARYA large proportion of colorectal cancers (CRCs) display mutational inactivation of the TGF-b pathway, yet,
paradoxically, they are characterized by elevated TGF-b production. Here, we unveil a prometastatic
program induced by TGF-b in the microenvironment that associates with a high risk of CRC relapse upon
treatment. The activity of TGF-b on stromal cells increases the efficiency of organ colonization by CRC cells,
whereas mice treated with a pharmacological inhibitor of TGFBR1 are resilient to metastasis formation.
Secretion of IL11 by TGF-b-stimulated cancer-associated fibroblasts (CAFs) triggers GP130/STAT3 signaling
in tumor cells. This crosstalk confers a survival advantage to metastatic cells. The dependency on the TGF-b
stromal program for metastasis initiation could be exploited to improve the diagnosis and treatment of CRC.INTRODUCTION
Most colorectal cancers (CRCs) originate from the intestinal
epithelium as premalignant lesions called adenomas. Over
time, a small fraction of adenomas are transformed to CRCs
because of the accumulation of genetic alterations in a small
set of driver genes, including KRAS, TP53, SMAD4, or PIK3CASignificance
About 40%–50%of all patients with colorectal cancer will prese
rent disease upon intended curative therapy. In the absence of
a major challenge to predict which patients will develop metas
that metastasis depends on a gene program expressed by
stromal TGF-b signaling is a robust predictor of disease-free
staging system. Furthermore, colonization of foreign organs r
be a target for therapeutic intervention at early time points of
Can(Markowitz and Bertagnolli, 2009). Alterations in these and other
cancer-causing genes have been associated with the different
stages of the progression of the tumor (i.e., transition from
normal intestinal mucosa to adenoma and further progression
to CRC). In contrast, metastases that are either present at the
time of diagnosis or develop as distant relapses after therapy
are not strongly associated with alterations in any of these keynt withmetastasis either at the time of diagnosis or as recur-
genetic alterations that explicate these processes, it remains
tatic disease or to design targeted therapies. Here, we show
the tumor microenvironment upon TGF-b stimulation. Low
survival after therapy, which improves on the current AJCC
equires TGF-b signaling in stromal cells and therefore may
the metastatic process.
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Stromal TGF-b Signals in Colon Cancer Metastasisgenes (Walther et al., 2009). In addition, global genome sequenc-
ing of metastatic lesions and primary CRCs revealed hardly any
metastasis-specific mutation (Jones et al., 2008). This drawback
has hampered the development of metastasis-specific thera-
pies, as well as the identification of patients with CRC at risk of
suffering metastatic disease.
Mutational inactivation of the TGF-b signaling pathway is key
during CRC progression. Alterations in TGF-b pathway compo-
nents are first detected in advanced adenomas and affect
40%–50% of all CRCs (Markowitz et al., 1995; Markowitz and
Bertagnolli, 2009). In mouse models, mutations in the tumor
suppressor Apc combined with inactivation of TGF-b signaling
components in epithelial intestinal cells trigger the development
of invasive adenocarcinomas (Mun˜oz et al., 2006; Takaku et al.,
1998). Restoration of a functional TGF-b pathway in human CRC
cells abrogates proliferation and tumorigenicity (Wang et al.,
1995), implying that TGF-b signaling exerts tumor-suppressive
effects. Hence, it has been proposed that TGF-b imposes
a selective pressure during CRC progression, which tumors
avert by genetic inactivation of the TGF-b receptors (TGFBR1
and TGFBR2) or of the SMAD intracellular mediators (SMAD4,
SMAD2, and SMAD3) (Grady and Markowitz, 2002; Markowitz
et al., 1995; Markowitz and Bertagnolli, 2009).
In addition to its tumor suppressor role in epithelial cells,
TGF-b signaling also acts as a negative regulator of tumor forma-
tion by conditioning mucosa-resident stromal cells. Mice with
a deletion of Smad4 in T cells develop gastrointestinal tumors
(Hahn et al., 2011; Kim et al., 2006). Similarly, transgenic expres-
sion of a dominant negative TGFBR2 in T cells accelerates
azoxymethane-induced colon carcinogenesis (Becker et al.,
2004). In both cases, T cells lacking TGF-b signals exacerbate
the production of proinflammatory cytokines that spark off
the transformation of the colonic epithelium (Becker et al.,
2004; Kim et al., 2006).
Although the above genetic and mutational data support
a tumor suppressor role for TGF-b signaling in intestinal carcino-
genesis, high levels of TGFB1 in the serum of patients with
CRC are associated with poor outcome in the clinical setting
(Tsushima et al., 2001). The relevance of TGF-b signaling for
disease progression has been widely recognized in tumors
where cancer cells retain a functional TGF-b pathway, such as
breast or prostate cancer (Massague´, 2008). In these tumor
cells, TGF-b induces a variety of prometastatic programs that
range from induction of epithelial-to-mesenchymal transition to
expression of genes that allow colonization of foreign organs
(Massague´, 2008). It is less clear, however, what CRC cells
can gain from high TGF-b levels once the pathway is fully
inactivated by mutations and how this phenomenon links to
an adverse outcome. To address this apparent paradox, we
investigated whether TGF-b may activate the tumor microenvi-
ronment to assist CRC cells in the metastatic process.
RESULTS
TGF-b Levels in CRC Are a Robust Predictor of Disease
Relapse
We first investigated whether differences in TGF-b levels in
primary tumors were associated with clinical disease progres-
sion in CRC. To this end, we interrogated a representative572 Cancer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Incpooled cohort of 345 cases treated at three different hospitals
for which transcriptomic profiles and clinical follow-up were
publicly available. In this metacohort, overall TGF-b levels were
low in patients with American Joint Cancer Committee (AJCC)
stage I cancer, compared to cancer at more advanced stages
(Figure 1A; see Tables S1 and S2 available online). The AJCC
staging system has limited power to predict disease relapse,
because 10%–20% of patients with stage II CRC and 30%–
50% of patients with stage III CRC will develop recurrent cancer
after therapeutic intervention. We found that, for every increase
in overall TGF-b (TGFB) expression, the risk of cancer recurrence
augmented by 83% (Figure 1B). As a consequence, we observed
large differences in the frequency of disease relapse after
therapy in patients bearing tumors with high, medium, or low
TGFB (Figure 1C) or individual TGF-b isoform levels (Figures
S1A and S1B). During 10 years of follow-up, only patients with
medium or high TGFB expression in the primary tumor (53 of
220 patients) suffered cancer recurrence. Remarkably, all
patients bearing TGFB-low tumors remained disease-free (Fig-
ure 1C, blue group). High TGFB levels were robustly associated
with relapse in patients with stage II and III cancer, whereas low
TGFB characterized a small set of patients with no observed
recurrences in both stages (Figure 1D; 17% and 11% of patients
with cancer at these stages, respectively). The rare relapses
occurring in stage I CRCs (2 of 35 patients in this group) also
expressed high TGFB levels (Figure 1D), although this com-
parison did not reach statistical significance, probably because
of the low incidence of recurrences in this stage. Cox propor-
tional hazards multivariate analysis demonstrated that TGFB
expression is an independent predictor of cancer recurrence
that outperforms AJCC staging system in the identification of
patients with CRC who remained disease free upon therapy
(Figure 1E). The predictive power of TGFB levels also compared
favorably to that of other genes that have been repeatedly asso-
ciated with disease relapse in CRC (Table S3).
TGF-b Response Signatures in Tumor-Associated
Stromal Cells Predict Disease Relapse in CRC
An increase in TGF-b isoform levels was evident at the adenoma-
CRC transition, as shown by expression profiling of a small
cohort of colon tumors (Figure S1C). Nuclear p-SMAD3, amarker
for TGF-b signaling, stained predominantly the stromal com-
partment in most CRCs (Figure S1D). In the majority of samples,
epithelial CRC cells were markedly less stained compared to
adjacent stromal cells or to the epithelial compartment of
adenomas (Figures S1D–S1F). We characterized the stromal
cell types stained by p-SMAD3 in CRCs but could not discrimi-
nate any obvious cell-type specificity. Rather, p-SMAD3 indis-
criminately labeled all major types of stromal cells in CRCs,
including T cells, macrophages, endothelial cells, and fibroblasts
(Figures S2A–S2H). We thus quantified the association of
TGF-b-activated stromal cell populations with disease progres-
sion. To this end, we used as surrogates the gene expression
programs induced by the addition of TGF-b (TGF-b response
signatures or TBRS) in cultures of normal-tissue-derived T cells
(T-), macrophages (Ma-), endothelial cells (End-), or fibroblasts
(F-). To avoid biases, we used the full set of genes upregulated
by TGF-b signaling in these cell cultures (>2 fold, p < 0.05)
without additional filtering or refinement (Table S4). By Gene.
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Figure 1. High TGF-b Expression Predicts CRC Relapse
(A) Overall TGFBmRNA expression in CRC stages I–IV. Values are z-scores with standard deviation (SD) from the mean (**p < 0.01, two-tailed Student’s t test).
(B) Smooth function correlates overall TGFB mRNA expression with relative risk of recurrence. Patients with stage IV cancer were excluded from this analysis.
Red dashed lines: 95% confidence interval (CI). Blue dashed lines: thresholds for patient selection into groups with low (L; blue, 44 patients), medium (M; gray, 86
patients), and high (H; red, 134 patients) TGFB expression; p values and increase in HR per each increase in standard deviation of expression (+1 SD) are shown.
(C and D) Kaplan-Meier plots display recurrence-free survival (RFS) over time (C) and grouped by AJCC stage (D) for groups defined in (B) . HR and p values
compare RFS over time for patients grouped according to TGFB levels (L versus M, L versus H, and M versus H).
(E) Cox proportional hazards multivariate analysis of TGF-b expression and AJCC staging in identifying patients who remained disease-free upon therapy.
See also Figure S1.
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Stromal TGF-b Signals in Colon Cancer MetastasisSet Enrichment Analysis (GSEA) (Subramanian et al., 2005), we
determined that all stromal TBRSs were highly enriched in
CRCs compared to adenomas (Figure 2A). Importantly, the
expression levels of TGFB, F-TBRS, T-TBRS, and Ma-TBRS
showed robust direct correlations in the cohort of patients with
CRC (Figure 2B), implying that they are, to a large extent, concur-
rently expressed in CRC. Significantly, these three signatures
were excellent predictors of disease relapse in patients with
stage I, II, and III CRC and segregated a low-expression patient
group with virtually no risk of developing recurrent cancer after
therapy (Figures 2C and 2D, blue group). This result paralleled
that obtained with TGFB levels (Figure 1). In patients with
stage IV CRC who underwent potential curative therapy, high
TGFB and stromal TBRS expression levels also correlated
with higher risk of relapse (Figures S2I–S2L). However, a large
proportion of these patients with stage IV disease eventually
experienced relapse, likely because of the lack of effective
therapies to eliminate an overt metastatic disease. Consistent
with their ability to predict disease progression, the stromal
TBRS included several well-known prometastatic genes, such
as ANGPTL4 (Padua et al., 2008), PTHLH (Yin et al., 1999),
HBEGF (Bos et al., 2009), CTGF (Kang et al., 2003), TNC
(Oskarsson et al., 2011), or JAG1 (Sethi et al., 2011; Sonoshita
et al., 2011), all of which encode for secreted or membrane-
bound factors (Table S4).
To further analyze the cell-type-specific expression of each
stromal TBRS in vivo, we purified by FACS various cell popu-
lations from fresh CRC samples and assessed their gene
expression profiles (Figures 2E and 2F). Relative levels of
cell-type-specific marker genes confirmed the purification of
epithelial tumor cells (EPCAM+), leukocytes (CD45+), endothelial
cells (CD31+), and fibroblasts (FAP+) (Figure 2F). A global
comparative analysis revealed a trend toward high levels of all
stromal TBRS in FAP+ CAFs. Conversely, epithelial tumor cells
expressed the lowest levels of each stromal TBRS (Figure 2G).
Remarkably, these trends became very significant for those
genes within the T-TBRS, Ma-TBRS, or End-TBRS that associ-
ated positively with cancer relapse (HR > 1, p < 0.05; Figure 2H).
Although the in vitro derived End-TBRS did not predict disease
progression (Figures 2C and 2D), we observed elevated ex-
pression of recurrence-associated TGF-b target genes in
endothelial cells directly purified from tumors (Figure 2H). This
observation may suggest that the response of in vitro culturedFigure 2. Stromal TGF-b Gene Signatures Predict Recurrence
(A) Gene set enrichment analyses (GSEA) of TGF-b response signatures (TBR
endothelial cells (End-TBRS) in carcinoma versus adenoma samples. ES, enrich
(B) Cross-correlations between TGFB, F-TBRS, T-TBRS, Ma-TBRS, and End-TB
are Z scores (*p < 0.05, ***p < 0.001).
(C) The p values and increase in HR per each increase in expression (+1SD) in F-
Hazards model.
(D) Kaplan-Meier plots display RFS of patients with low (blue), medium (gray), or
(E) FACS-purification of cell populations from primary CRC samples, enriched in
(F) Heat map shows relative expression levels of marker genes for epithelial (blue
(green) in each cell population. Values are normalized intensities, log2.
(G) Relative expression of each TBRS in cell populations from (F). Whiskers repre
interquartile range (log2; *p < 0.05, **p < 0.01, Student’s t test).
(H) Relative expression in each cell population of genes within the T-TBRS,Ma-TB
Vmax (log2; *p < 0.05, **p < 0.01, Student’s t test).
See also Figure S2.
Canendothelial cells to TGF-b signaling deviates significantly from
that occurring in the tumor microenvironment. Altogether, these
data highlight that the response of stromal cells to TGF-b is an
accurate predictor of disease relapse in patients with CRC.
Although high TGFB levels activate gene programs in a wide
range of tumor-associated stromal cell types, our in vivo data
indicate that CAFs and, to a lesser extent, endothelial cells are
the main contributors to the association of stromal TGF-b-driven
programs with poor outcome after therapy.
TGF-b Signaling in the Stroma Promotes Tumor
Initiation
The above data suggest the possibility that elevated TGFB levels
in CRC influence disease progression by acting on stromal cells.
To functionally dissect this effect without the interference of
TGF-b signaling in epithelial cancer cells, we took advantage
of the fact that virtually all late-stage CRC-derived cell lines
display mutational inactivation of the TGF-b pathway. These
CRC cell lines, however, did not induce robust stromal TGF-b
responses when injected into nude mice, as shown by the lack
of p-SMAD2 accumulation in tumor-associated stromal cells
(arrows in Figures 3A and 3B; data not shown). To enforce high
TGF-b signaling in xenografts, we engineered CRC cell lines to
secrete active TGFB1. Subcutaneous tumors obtained from
HT29-M6TGF-b, KM12L4aTGF-b and SW48TGF-b cells contained
abundant p-SMAD2+ stromal cells (arrowheads in Figures 3A
and 3B; data not shown) and increased expression levels of
stromal TBRS genes (Figure 3C; data not shown). Importantly,
secretion of TGF-b did not induce autocrine responses in these
CRC cells (i.e., SMAD reporter activity, proliferation, or EMT
induction; Figures S3A–S3D), owing to homozygous mutations
in TGFBR2 in KM12L4a and in SW48. HT29-M6 cells carry
homozygous inactivation of the SMAD4 locus, which rendered
this cell line unresponsive to TGF-b (Figures S3A–S3D). Yet,
this genetic alteration did not impede the nuclear accumulation
of p-SMADs (Figure 3B), as previously reported for other
SMAD4 mutant cell lines (Alarco´n et al., 2009; Liu et al., 1997).
Therefore, the xenografts derived from these cells combine
a TGF-b response in tumor stromal cells with lack of TGF-b
signaling in cancer cells, the scenario characteristic of advanced
CRC. We inoculated CRC cells subcutaneously into nude mice
in quantities that generated suboptimal engraftment in control
conditions (see Experimental Procedures). Elevated levels ofS) of Fibroblasts (F-TBRS), T cells (T-TBRS), macrophages (Ma-TBRS), or
ment score; NES, normalized enrichment score; FDR, false discovery rate.
RS in the patient cohort. Blue dots, patients. R, correlation coefficients. Values
TBRS, T-TBRS, Ma-TBRS, and End-TBRS were obtained via Cox proportional
high (red) F-TBRS, T-TBRS, Ma-TBRS, or End-TBRS expression levels.
the indicated cell types.
), leukocyte (red), endothelial (orange) cells, and cancer-associated fibroblasts
sent minimum (Vmin) and maximum (Vmax) values, truncated at 1.5 times the
RS, End-TBRS, or F-TBRS associating positively with relapse. Whiskers: Vmin,
cer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Inc. 575
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Figure 3. TGF-b Activated Stroma Induces Tumor Initiation
(A and B) Nuclear p-SMAD2 reactivity (arrowheads) in subcutaneous (s.c.) tumors derived from TGF-b-secreting KM12L4a (A) or HT-29M6 (B) CRC cells and
control cells. E, epithelial cells; Str, stromal cells. Scale bars = 10 mm.
(C) Relative expression of some stromal TBRS genes in tumors from (B). Values are mean ± SEM (n = 3).
(D) Kaplan-Meier plots display tumor-free survival (TFS) for mice injected s.c. with 33 104 TGF-b-secreting (red) or control cell lines (blue); SW48 (n = 8); KM12L4a
(n = 8); HT29-M6 cells (n = 25 (red), n = 39 (blue).
(E) Growth over time for HT29-M6TGF- b (red; n = 13) and HT29-M6Con (blue; n = 16) derived tumors. Day 1: day of first detection. Values are mean ± SEM.
(F) Relative TGFB mRNA levels in HT29-M6 cells expressing active TGF-b through a doxycycline (Dox)-inducible promoter (HT29-M6 ind. TGF-b) compared to
control cells (Con, blue). Inducible TGF-b cells were nontreated (gray), treated with Dox for 24 hr (black), or treated with Dox for 24 hr followed by 24 hr of Dox
withdrawal prior to qRT-PCR (red). Values are mean ± SD (n = 3).
(G) Inducible TGF-b cells were either untreated (blue) or pretreated with Dox in vitro 24 hr before s.c. inoculation (3 3 104 cells; n = 6). Recipient mice received
either Dox (red) or vehicle (blue) in drinking water ad libitum during 3 days prior to injection. Kaplan-Meier curves show TFS when TGF-b secretion is induced
in vivo for 24 hr (red) compared to control cells (blue).
See also Figure S3.
Cancer Cell
Stromal TGF-b Signals in Colon Cancer MetastasisTGF-b dramatically increased the frequency of tumor formation
and reduced the latency period in all cell lines (Figure 3D). Yet,
after tumor initiation, the TGF-b-activated microenvironment
had no effect on xenograft growth rates (Figure 3E; data not
shown). We further tested this early requirement by controlling
the timing of TGF-b production in HT29-M6CRC cells via a doxy-
cycline-inducible promoter (Figures 3F and 3G). Secretion of576 Cancer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier IncTGF-b during the first 24 hr following inoculation of tumor cells
was sufficient to enhance tumor initiation (Figure 3G). Given
the well-established role of TGF-b in the polarization and
suppression of the immune system in tumors (Flavell et al.,
2010), we tested whether the enhancement of tumor initiation
by TGF-b signaling could be explained by modulation of the
immune system. To this end, we injected CRC cells in severely.
Cancer Cell
Stromal TGF-b Signals in Colon Cancer Metastasisimmunocompromised mice of the NOD/SCID interleukin-2
receptor gamma chain null strain (NSG) (Shultz et al., 2007). In
these NSG mice, high TGF-b levels were also capable of
enhancing tumor initiation, although fewer cancer cells were
required to form tumors in this strain (Figure S3E).
Stromal TGF-b Signaling Is Required for Efficient
Metastasis Initiation
CRCs at stages I, II, and III displaying low stromal TGF-b
signaling fail to form recurrences, which, in most patients with
CRC, occur in the form of metastasis. To study whether stromal
TGF-b signaling may influence metastasis formation, we inocu-
lated KM12L4aCon and KM12L4aTGF-b cells in the cecum of
nude mice. Both cell lines gave rise to aggressive colorectal
tumors, which killed mice by obstruction of the intestinal lumen.
At death, KM12L4aCon and KM12L4aTGF-b had generated colon
tumors of equivalent size (data not shown) with no significant
differences in their degree of invasion, spread to local lymph
nodes, or major histological features (Figure 4A; Figures S4A
and S4B). Yet, two thirds of mice bearing KM12L4aCon colon
tumors remained metastasis free, whereas 10 of 11 mice inocu-
lated with KM12L4aTGF-b cells developed lung and/or liver
metastasis (p < 0.01, Figure 4B). These data imply that stromal
TGF-b signaling promotes metastasis formation. We further
explored this phenomenon by using intrasplenic inoculation of
CRC cells (Morikawa et al., 1988). Secretion of TGF-b by
KM12L4a cells increased the liver metastases burden in mice
(Figure 4C). We also observed a large increase in the number
of liver metastases generated by HT29-M6 secreting TGF-b
(Figure 4D). In addition, a significant fraction of mice inoculated
with KM12L4aTGF-b or HT29-M6TGF-b developed lung metas-
tases, implying that TGF-b signaling also facilitated secondary
organ colonization (Figure 4E). The kinetics of liver metastasis
revealed that control or TGF-b secreting cells expanded with
similar rates once tumor cells had taken root and resumed
growth (from day 7 in Figure 4F). However, during the first few
days following inoculation, most KM12L4aCon cells that reached
the liver were progressively lost, and by 7 days, tumor cells were
barely detectable (Figure 4F). A virtually complete loss of control
metastatic cells was noticed during the first 24 hr upon inocu-
lation of lower tumor cell numbers (Figure S4C). Secretion of
TGF-b significantly increased the amounts of KM12L4a cells
detected at these early time points (Figure 4F; Figure S4C). To
further test this early requirement, we used CRC cells that ex-
pressed TGF-b from a doxycycline-inducible promoter. A short
pulse of TGF-b (24 hr) at the moment of intrasplenic inoculation
was sufficient to increase metastasis burden by facilitating
metastasis initiation without affecting subsequent tumor growth
(Figures 4G and 4H; Figure S4D; p < 0.05). Thus, high levels of
TGF-b specifically act to enhance the colonization capability of
CRC cells at the initial phase of metastasis. Because KM12L4a
and HT29-M6 cells harbor an inactivated TGF-b pathway,
enhanced metastasis initiation by TGF-b secretion must be
the consequence of changes in the tumor microenvironment.
Indeed, metastasis derived by both TGF-b secreting cell lines
displayed enhanced desmoplastic reaction (Figures S4E–S4L)
with abundant p-SMAD2 accumulation in stromal cells (Figures
4I and 4J; Figures S4M and S4N) and elevated expression of
stromal TBRS genes (Figure 4K; data not shown).CanPharmacological Inhibition of Stromal TGF-b Signaling
Blocks Metastasis Initiation
We have recently described the purification of Colon Cancer
Stem Cells (CoCSCs) from CRC biopsies via surface expression
of the receptor tyrosine kinase EPHB2 (Merlos-Sua´rez et al.,
2011). We isolated EPHB2-high CoCSCs from the primary tumor
of a patient with stage IV CRC and cultured them in conditions
similar to those used for expansion of normal colon stem cells
(Jung et al., 2011; Sato et al., 2011). EPHB2-high tumor cells
embedded in matrigel expanded as epithelial tumor organoids
(Figure 5A), which retained high expression levels of colon
stem cell marker genes such as LGR5 and ASCL2 (data not
shown). Genomic analysis of the tumor organoids revealed that
the two TGFBR2 alleles were inactivated by mutations in this
patient (data not shown). Indeed, treatment with TGFBR1-
specific inhibitor LY2157299 (Bueno et al., 2008) or the addition
of active TGF-b did not modify in vitro growth rates, morphology,
or organoid forming activity of this CoCSC-derived culture
(Figures 5A–5C). Primary CoCSCs expressed higher TGFB
levels than did CRC cells lines (Figure 5D). When injected in
immunodeficient mice, they generated tumors with abundant
p-SMAD2+ stromal cells (Figure 5E, left panel), implying that
this primary CoCSCs elicited a TGF-b response in the tumor
microenvironment. Feeding mice bearing macroscopic tumors
from CoCSCs-derived cultures with LY2157299 blocked TGF-b
signaling in the tumor stroma as shown by reduced stromal
p-SMAD2 positivity (Figure 5E, right panel) and downregulated
levels of stromal TBRS genes (Figure 5F). Importantly, treatment
with LY2157299 conferred resistance to the formation of sub-
cutaneous tumors by primary CoCSC-derived cells (Figures 5G
and 5H). Remarkably, this TGF-b inhibitor regime also reduced
formation of liver metastasis by CoCSCs inoculated via the
spleen (Figures 5I and 5J). Kinetics of metastatic colonization
showed that LY2157299 reduced the number of cells that en-
grafted the liver immediately after inoculation (Figure 5I, inset),
the opposite behavior of that induced by secretion of high
TGF-b levels in CRC cell lines. Of note, these experiments
were performed in NSG mice, which rules out that LY2157299
blocked metastasis through changes in the function of the
immune system. Altogether, the clinical and functional data
described so far indicate that a TGF-b program activated in the
tumor microenvironment confers CRC cell competence to over-
come the initial phase of metastasis.
Metastasis Initiation by TGF-b-Stimulated Stromal
Cells Depends on GP130/STAT3 Signaling in Tumor
Epithelial Cells
We next sought to understand the mechanisms behind the
potent effect of stromal TGF-b program on the capacity of
CRC cells to initiate metastasis. We discovered that subcuta-
neous tumors and metastases generated in the context of a
TGF-b activated microenvironment displayed prominent accu-
mulation of p-STAT3 in CRC cells compared with those derived
from control cells (Figure 6A; Figures S5A–S5H). STAT3 sig-
naling depended on GP130 as shown by strong reduction of
epithelial p-STAT3 levels upon GP130 shRNA-mediated knock-
down in CRC cells (Figure 6A; Figures S5I and S5J). These
results suggest that TGF-b induces the expression of GP130-
binding cytokines in the tumor microenvironment, which in turncer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Inc. 577
BA
2/6 (33%)
Con TGF-β
10/11 (91%)**
0/6 (0%) 4/11 (36%)
2/6 (33%) 10/11 (91%)
Liver
Lung
Metastasis index
0/4 (0%) 3/4 (75%)
2/8 (25%) 7/9 (78%)
0/5 (0%) 2/5 (40%)
Con TGF-β
Con TGF-β
1x105 cells
5x105 cells
KM12L4a
Occurrence of lung mets
2x106 cells
HT29-M6
K
Submucosal
Invasion
Lymphatic vessel
Invasion 
Low Moderate High
EDC
Li
ve
r m
et
as
ta
se
s 4
2
0
*
Con
TGF-β
KM12L4a Con
KM12L4a TGF-β
105 cells
120
60
0
*
Con
TGF-β
TGF-β
ConHT29-M6
HT29-M6
2x106 cells
F
0.1
0 1 3 7 
Days
14 
1
10
100
1000
KM12L4a
Con
TGF-β
5 x 105 cells 
*
N
or
m
. p
ho
to
n 
flu
x 
(L
og
10
) 
KM12L4a KM12L4aCon TGF-β
Str
Str
E
p-
S
M
A
D
2
I
10
20
15
1
0
5
3
An
gp
tl2 Il1
1
m
R
N
A
 fo
ld
 in
du
ct
io
n
Se
rpi
ne
1
KM12L4a
TGF-β
Con
1
10
100
1000
0 1 2 4 6 8 11 15 18 20
*
Vehicle
DOX 24h
N
or
m
. p
ho
to
n 
flu
x 
(L
og
10
) 
Days
120
80
40
0
KM12L4a
*
Vehicle
DOX 24h
J
Li
ve
r m
et
as
ta
se
s
HG
E
KM12L4a
Con
TGF-β
KM12L4a
Figure 4. TGF-b Activated Stroma Induces CRC Metastasis
(A) Pie charts for submucosal or lymphatic vessel invasion in KM12L4acon- and KM12L4aTGF-b-derived cecum tumors.
(B) Incidence of metastases in mice from (A) (**p < 0.01; Fisher’s exact test).
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denote metastatic nodules.
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Figure 5. Inhibition of TGF-b Response in
the Stroma Blocks Tumor Initiation
(A) In vitro expansion of a CoCSC. Scale bars =
10 mm.
(B) In vitro growth of human CoCSCs upon addi-
tion of TGF-b or LY2157299 (LY). Values are mean
relative absorbance (RLU) over time ± SD (n = 3).
(C) Number of organoids from human CoCSCs
treated with TGF-b or LY2157299. Values are
mean ± SD (n = 3). Representative images are
shown. Scale bars = 200 mm.
(D) qRT-PCR for TGFB in the indicated CRC cells.
Values are mean ± SEM.
(E) p-SMAD2 staining in s.c. tumors derived from
CoCSCs injected in NSG mice treated with
LY2157299 for 3 days (LY; right panel, arrowhead)
or untreated (left panel; arrow). E, epithelial cells;
Str, stromal cells. Scale bars = 10 mm.
(F) Relative expression of some stromal TBRS
genes in tumors from (E). Values are mean ± SEM
(n = 2).
(G) Kaplan–Meier curves show TFS for mice in-
jected s.c. with 106 CoCSCs. Mice received
LY2157299 (blue) or vehicle (purple) from 3 days
prior to inoculation until sacrifice (n = 12).
(H) Representative images from (G).
(I) Bioluminescence over time after IS inoculation
of 5 3 105 CoCSCs cells in NSG mice treated as
in (G). Values, normalized as in Figure 4F, are
mean ± SEM.
(J) Representative images from (I).
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Stromal TGF-b Signals in Colon Cancer Metastasisswitches on STAT3 signaling in tumor epithelial cells. To study
the relevance of this signaling cycle for tumorigenesis, we inoc-
ulated subcutaneously into nude mice HT29-M6 cells that
secreted active TGFB1 and at the same time were knockdown
for GP130 (HT29-M6shGP130/TGF-b). These experiments revealed(E) Incidence of metastasis induced in (C), (D), and (F).
(F) Normalized bioluminescence over time after injection of 53 105 KM12L4aCon or KM12L4aTGF-b cells. Inten
100. Values are mean ± SEM (*p < 0.05).
(G and H) Inducible TGF-b cells and recipient mice were treated as in Figure 3G. (G) Bioluminescence ov
normalized as in (F), are mean ± SEM (*p < 0.05). (H) Number of liver metastases at time of sacrifice. Whiskers:
(I and J) p-SMAD2 staining in liver metastasis generated from KM12L4aCon (I) or KM12L4aTGF-b cells (J). E, ep
(K) Relative expression levels of some stromal TBRS genes in dissected metastatic nodules. Values are me
See also Figure S4.
Cancer Cell 22, 571–584, Nthat GP130/STAT3 signaling in cancer
cells participated in the enhancement
of tumor initiation mediated by stromal
TGF-b signaling (Figure 6B), but it was
not important for the growth of tumors
once established (Figure 6C). HT29-
M6shCon or HT29-M6shGP130 cells grew
with identical kinetics in vitro (Figure S5K)
and, in the absence of a source of TGF-b,
formed tumors in immunodeficient mice
with equivalent latency and frequency
(Figure S5L).
Importantly, these GP130-knockdown
HT29-M6 cells secreting TGF-b displayed
decreased liver take rates during the firsthours following intrasplenic inoculation (Figures 6D and 6E)
compared to control cells. After the initial phase, the number
of tumor cells detected in the liver progressively decreased
and, after two weeks, both HT29-M6shCon/TGF-b and HT29-
M6shGP130/TGF-b cells reinitiated expansion with similar kineticssities were normalized to day 0 and arbitrarily set to
er time after injection with 5 3 105 cells. Values,
Vmin, Vmax (*p < 0.05, two-tailed Student’s t test).
ithelial cells; Str, stromal cells. Scale bars = 10 mm.
an ± SEM (n = 3).
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Figure 6. Metastasis Initiation Driven by
Stromal TGF-b Signaling Requires GP130/
STAT3 in Tumor Cells
(A) p-STAT3 staining in s.c. tumors derived from
control (HT29-M6shCon, left panel) cells, HT29-M6
cells that secrete TGF-b (HT29-M6shCon/TGF-b,
middle panel), or HT29-M6 shGP130 cells that also
secrete TGF-b (HT29-M6shGP130/TGF-b, right panel).
Arrows point to epithelial tumor cell nuclei. E,
epithelial cells; Str, stromal cells. Scale bars =
50 mm.
(B) Kaplan-Meier curves for mice injected with
3 3 104 HT29-M6shGP130/TGF-b (blue) or HT29-
M6shCon/TGF-b cells (red; n = 16).
(C) Growth kinetics of HT29-M6shGP130/TGF-b (blue)
and HT29-M6shCon/TGF-b (red) s.c. xenografts
(n = 5). Day 1: day of first detection. Values are
mean ± SEM.
(D) Bioluminescence over time after IS inocu-
lation of 23 106 HT29-M6shCon/TGF-b (red) or HT29-
M6shGP130/TGF-b (blue) cells. Values, normalized as
in Figure 4F, are mean ± SEM (n = 4; *p < 0.05).
(E) Bioluminescence from (D) 24 hr after IS injec-
tion. Whiskers: Vmin, Vmax (**p < 0.01, two-tailed
Student’s t test).
(F) In vivo measurement of caspase 3/7 activity in
CRC cells 6 hr after IS injection. Values are mean
ratios between caspase activity and total cellular
bioluminescence ± SEM (n = 3).
See also Figure S5.
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Stromal TGF-b Signals in Colon Cancer Metastasis(Figure 6D). The initial clearance of tumor cells is concurrent
with apoptosis, as shown by measurement of in vivo caspase
activity few hours after inoculation (Figure 6F). In the absence
of GP130/STAT3 signaling, apoptosis levels were increased,
suggesting that this pathway promotes survival in the context
of liver colonization.
Interleukin-11, a TGF-b Target Gene in CAFs, Enhances
Metastasis Initiation
Interleukin-11 (IL11), a GP130-binding cytokine, was among the
genes highly upregulated by TGF-b in colon fibroblast cultures
(F-TBRS, Table S4), although microarray measurements of
IL11 mRNA levels did not associate with cancer recurrence
in the cohort of patients with CRC (Table S4). HT29-M6 CRC
cells responded to recombinant IL11 by activating the GP130/
STAT-3 pathway (Figure 7A). Genes upregulated by IL11 in
this cell line constituted an IL11-response signature (IL11RS,
Table S4). We found that IL11RS expression correlates tightly
with both TGFB and FTBRS levels in CRC samples (Figure 7B)
and predicts disease relapse (Figures 7C and 7D). Purification
of stromal populations from primary human CRC samples
showed that CAFs were the only source of IL11 in tumors
(Figure 7E). Experimental metastasis generated from TGF-b
secreting KM12L4a cells showed a marked upregulation of
IL11 (Figure 7F). Importantly, IL11mRNAwas reduced to control
levels upon LY2157299 treatment of mice bearing CRC stem
cell-derived tumors (Figure 7F).
We tested the contribution of IL11 to metastasis by engi-
neering CRC cells to autonomously produce this cytokine.
Upon implantation in the cecum of mice, we observed no signif-580 Cancer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Incicant differences in the size (not shown), degree of invasion
(Figure 7G), or histological appearance of primary tumors devel-
oped by control or study groups (Figures S6A–S6C). Yet,
KM12L4aIL11 cells effectively colonized liver, lungs, distant
lymph nodes, and brain, whereas control cells displayed limited
metastatic capacity (Figure 7G, inset table). In the same set of
experiments, KM12L4a cells expressing IL6, a cytokine closely
related to IL11, displayed a marginal increase in metastatic
capacity (Figures S6D and S6E). Intrasplenic inoculation of
HT29-M6IL11 tumor cells confirmed that IL11 enhanced the
liver metastatic potential of CRC cells (Figures 7H–7K). The initial
kinetics of metastasis upon intrasplenic inoculation demon-
strated that IL11-expressing cells were more proficient at colo-
nizing livers than were control cells (Figures 7I and 7J), an effect
that was evident as early as 24 hr after inoculation (Figure 7K).
IL11 rescued apoptosis of tumor cells during the first hours of
liver colonization (Figure 7L). This behavior paralleled that
induced by stromal TGF-b through GP130 signaling in CRC cells
shown in Figures 6D–6F.
DISCUSSION
Metastasis involves the regeneration of a full-blown tumor from
few disseminated cancer cells. This process is intrinsically
inefficient, mainly because of the inability of isolated tumor cells
to colonize host tissues and reinitiate tumor growth in a different
environment (Luzzi et al., 1998; Valastyan and Weinberg, 2011).
The most accepted view is that competences to overcome this
initial bottleneck result from Darwinian selection of appropriate
genetic alterations in CRC cells. It is not clear, however, how.
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Figure 7. Stromal TGF-b-Induced IL11
IncreasesMetastasis Initiation byCRCCells
(A) Western blot of p-STAT3 and total STAT3 in
CRC epithelial cells upon addition of rhIL11.
(B) Cross-correlation analysis between expression
of IL11 response signature (IL11RS) and TGFB
or F-TBRS in the cohort of patients with CRC.
Blue dots, patients. R values are indicated
(***p < 0.001).
(C) Smooth function correlates IL11RS expres-
sion with relative risk of recurrence, patients with
stage IV disease excluded. Red dashed lines:
95% CI. Blue dashed lines: thresholds for selec-
tion into groups with low (L; blue, 42 patients),
medium (M; gray, 88 patients), and high (H; red,
134 patients) IL11RS expression levels. HR (+1SD)
and p values are indicated.
(D) Kaplan-Meier plots with RFS for groups defined
in (C).
(E) IL11 mRNA levels in the indicated tumor cell
populations from six patients. qRT-PCR values are
mean ± SD.
(F) Relative expression levels of IL11mRNA in liver
metastasis from IS injection with KM12L4aCon
(blue) or KM12L4aTGF-b (red) (n = 3) and from s.c.
tumors generated by CoCSCs treated with either
vehicle (Con, purple) or LY2157299 (dark blue)
(n = 2). Values are mean ± SEM.
(G) Pie charts evaluate submucosal or lymphatic
vessel invasion in KM12L4acon-derived (n = 7) and
KM12L4aIL11-derived (n = 8) cecum tumors. Table
shows incidence of metastasis in mice (**p < 0.01,
Fisher’s exact test).
(H–L) Mice inoculated IS with 23 106 HT29-M6Con
cells (blue; n = 7) or HT29-M6IL11 cells (gray; n = 4).
(H) Quantification and representative pictures
of liver metastases (arrows) at time of sacrifice
(*p < 0.05, two-tailed Student’s t test). Whiskers:
Vmin, Vmax, truncated at 1.5 times the inter-
quartile range. (I) Bioluminescence over time after
IS inoculation. Values, normalized as in Figure 4F,
are mean ± SEM (**p < 0.01). (J) Representative
images from (I). (K) Bioluminescence 24 hr after
injection in mice from (I). Whiskers: Vmin, Vmax
(**p < 0.01, two-tailed Student’s t test). (L) In vivo
caspase 3/7 activity 6 hr after IS injection of
HT29-M6con or HT29-M6IL11 cells. Values are
mean ± SEM.
See also Figure S6.
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Stromal TGF-b Signals in Colon Cancer Metastasisfunctions required for colonizing a foreign organ could be
selected in the primary tumor where the specific constraints
imposed by a different tissue environment are not present
(Luzzi et al., 1998; Valastyan and Weinberg, 2011). Additionally,
metastatic traits could be acquired after cancer cells have
reached the metastatic site, yet this event would necessarily
require that tumor cells gain extravasation capacity and survive
in the host environment. Our data argue that key functions
required to overcome the initial phase ofmetastasis are provided
by the TGF-b-activated microenvironment. Without the activity
of this stromal program, fully aggressive CRC cells fail to colo-
nize the host organ. We speculate that those tumor cells capable
of initiating metastasis with high efficiency would possess the
capacity to raise such TGF-b response in the environment.CanDuring metastatic colonization, tumor cells may instruct the
stroma of the host organ by either secreting TGF-b or recruiting
TGF-b-producing cells such macrophages, CAFs, or platelets.
An alternative hypothesis is that a TGF-b-driven premetastatic
niche could be specified by the primary tumor in foreign tissues
through secretion of systemic cytokines, including TGF-b itself.
Among the benefits that CRCs obtain via crosstalk with the
TGF-b-subverted microenvironment is GP130/STAT3 signaling,
which suppresses apoptotic stimuli encountered during the
colonization of the metastatic site. Fitting these observations,
it has been shown that p-STAT3 accumulation in primary
CRC samples associates to advanced disease and poor out-
come (Kusaba et al., 2006; Morikawa et al., 2011). Indeed, the
GP130-binding cytokine IL11, which is secreted by TGF-bcer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Inc. 581
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cells. On a side note, IL11 is also a megakaryopoietic cytokine
that stimulates platelet production (Musashi et al., 1991; Tera-
mura et al., 1992), and recombinant IL11 is an efficient
supportive therapy in patients with malignancies who develop
thrombocytopenia as a side effect of chemotherapeutic treat-
ment (Bhatia et al., 2007). Therefore, the prometastatic effect
of IL11 described here calls for a reassessment of the use of
this cytokine in an adjuvant setting. On the other hand, correla-
tions between elevated platelet counts, referred to as thrombo-
cytosis, and poor prognosis have been reported for many solid
cancers, including gastrointestinal tumors (Ikeda et al., 2002;
Nouso et al., 2008). Platelets protect circulating tumor cells
from immune system, aswell as assist themduring extravasation
(Gay and Felding-Habermann, 2011). In addition, platelets are
a rich source of TGF-b (Labelle et al., 2011). It is thus possible
that tumor-derived TGF-b may promote IL11 production from
stromal cells to increase platelet activation, which may further
enhance stromal TGF-b response.
Besides IL11, the TGF-b response signatures include some
previously described prometastatic factors in other tumor types,
such as ANGPTL4 (Padua et al., 2008), PTHLH (Yin et al., 1999),
HBEGF (Bos et al., 2009), CTGF (Kang et al., 2003), TNC
(Oskarsson et al., 2011), and JAG1 (Sethi et al., 2011; Sonoshita
et al., 2011). For instance, ANGPTL4 mRNA levels are induced
by TGF-b in fibroblasts (Table S4). This secreted factor has
been previously shown tomediate intravasation of breast cancer
cells into lungs (Padua et al., 2008). Consistent with this obser-
vation, our assays show enhancement of lung metastatic
capacity byCRCcells upon activation of stromal TGF-bprogram.
JAG1 participates in breast cancer metastasis to the bone (Sethi
et al., 2011), and activation of Notch signaling in CRC cells by
endothelial cell-expressed JAG1 promotes transendothelial
migration during liver and lung metastasis (Sonoshita et al.,
2011). Indeed, we found that JAG1 is a TGF-b response gene
in endothelial cells (Table S4). Therefore, besides survival during
the colonization phase of metastasis, the program activated
by TGF-b in the microenvironment likely influences additional
functions required to complete the metastasic process. Impor-
tantly, in contrast to CRC, the expression of ANGPTL4, PTHLH,
CTGF, or JAG1 is induced autonomously in breast cancer
cells activated by TGF-b (Kang et al., 2003; Padua et al., 2008;
Yin et al., 1999). IL11 itself is a TGF-b target gene in breast
cancer cells, with an important role during bone metastasis
formation (Kang et al., 2005; Kang et al., 2003). It thus appears
that, in the context of a lack of response to TGF-b, CRC cells
instead achieve similar abilities by engaging the microenviron-
ment in a TGF-b-dependent manner. It would be interesting to
analyze whether this may be a general response in other cancer
types that bear inactivating mutations in TGF-b pathway com-
ponents, such as pancreatic cancer.
The invasive adenocarcinomas developed in mouse models
bearing compound mutations in Smad4 and Apc course with
a prominent accumulation of reactive stroma (Kitamura et al.,
2009; Takaku et al., 1998). Although it is not clear whether this
effect depends on increased levels of TGF-b signaling in the
microenvironment, Tgfbr2 deletion in anApcmutant background
raises production of TGFB1 in tumors (Mun˜oz et al., 2006). It is
thus plausible that CRCs evolve toward a favorable scenario582 Cancer Cell 22, 571–584, November 13, 2012 ª2012 Elsevier Incfor metastasis by combining an increase of TGF-b signaling in
stromal cells with the acquisition of inactivating mutations in
TGF-b pathway components in the cancer cells. The majority
of CRCs display moderate-to-high TGF-b expression levels,
whichmay help explain the high rates of CRCmetastasis. Impor-
tantly, we discovered a subgroup of tumors (10%–20% of all
CRCs) displaying invasion and/or local dissemination (i.e.,
AJCC stage II and III) yet with low TGF-b production that did
not relapse after surgical intervention. Therefore, besides
AJCC staging, our findings call for the assessment of TGF-b
pathway activation in stromal cells as a central criterion for
patient stratification. Several targeted therapies against TGF-b
signaling, including LY2157299, are currently being evaluated
for treatment of different cancer types (Tan et al., 2009; Yingling
et al., 2004). Although their efficacy is not yet known, our ob-
servations predict that pharmacological inhibition of TGF-b
signaling may prevent CRC relapse and metastasis when treat-
ing patients at early time point of the process.
EXPERIMENTAL PROCEDURES
Profile Data Sets
We defined overall TGF-b levels (TGFB) as the average expression of TGFB1,
TGFB2, and TGFB3mRNAs in a given sample (see Supplemental Information).
Data sets corresponding to human colon adenomas and carcinomas have
been previously described (Sabates-Bellver et al., 2007; Van der Flier et al.,
2007). To correlate TGFB and TBRS expression with clinical disease progres-
sion, we pooled two publicly available sets of Affymetrix transcriptomic
profiles (GSE17537 and GSE14333) corresponding to primary CRCs for
which clinical follow-up was available. GSE17537 (Smith et al., 2010) is
composed of 55 patients with colon cancer treated at Vanderbilt University
Medical Center (Nashville, TN, USA). GSE14333 (Jorissen et al., 2009) contains
a pool of 290 patients with CRC treated at two different hospitals: Peter
MacCallum Cancer Center (Australia) and H. Lee Moffitt Cancer Center
(USA). The representation of tumor samples at different AJCC stages in
these cohorts follows the natural distribution of patients with CRC receiving
standard treatment in the aforementioned hospitals. Descriptive statistics
(Table S1) as well as univariate analysis of clinical progression parameters
(Table S2) in this metacohort are included as Supplemental Information. The
TGF-b response signatures used in this study are detailed in Table S4.
Orthotopic Mouse Studies
All experiments with mouse models were approved by the animal care and
use committee of the Barcelona Science Park (CEEA-PCB) and the Catalan
Government. Cells were injected subcutaneously in 5–6–week-old Swiss
nude or NSG mice (Jackson Laboratories), which were followed for the
periods described. Tumor appearance was assessed by palpation. Five-to-
six-week-old Balb/c nude or NSG mice (Jackson Laboratories) were used to
perform metastasis experiments by intrasplenic injection (Warren et al.,
1995) or intracecum injection (Ce´spedes et al., 2007).
Clinical Material
Biological samples were obtained from individuals treated at the Hospital del
Mar (Barcelona, Spain) or from Hospital Clinic (Barcelona, Spain) under
informed consent and approval of the Bank Tumor Committees of each
hospital according to Spanish Ethical regulations. The study followed the
guidelines of the Declaration of Helsinki and patient’s identity of pathological
specimens remained anonymous in the context of this study. Experiments
were approved by the ethics committee of IRB/Hospital Clinic (project ERC-
208488/CRCprogramme).
ACCESSION NUMBERS
The transcriptomic data sets generated for this study have been deposited
in GEO with accession number GSE39397. This SuperSeries contains the.
Cancer Cell
Stromal TGF-b Signals in Colon Cancer Metastasissubset series GSE39394, GSE39395, and GSE39396 as detailed in Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.08.013.
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